These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 22076962)

  • 21. Clinical Outcomes of Daptomycin for Vancomycin-resistant Enterococcus Bacteremia.
    Moise PA; Sakoulas G; McKinnell JA; Lamp KC; DePestel DD; Yoon MJ; Reyes K; Zervos MJ
    Clin Ther; 2015 Jul; 37(7):1443-1453.e2. PubMed ID: 25982687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance.
    Chong YP; Lee SO; Song EH; Lee EJ; Jang EY; Kim SH; Choi SH; Kim MN; Jeong JY; Woo JH; Kim YS
    Scand J Infect Dis; 2010 Jul; 42(6-7):491-9. PubMed ID: 20524781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections.
    Whang DW; Miller LG; Partain NM; McKinnell JA
    Antimicrob Agents Chemother; 2013 Oct; 57(10):5013-8. PubMed ID: 23896468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors and outcomes associated with vancomycin-resistant Enterococcus infections with reduced susceptibilities to linezolid.
    Santayana EM; Grim SA; Janda WM; Layden JE; Lee TA; Clark NM
    Diagn Microbiol Infect Dis; 2012 Sep; 74(1):39-42. PubMed ID: 22749382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evaluation of vancomycin-resistant Enterococcus cases at a tertiary level hospital in Izmir, Turkey].
    Atalay S; Ece G; Samlıoğlu P; Maraş G; Köse I; Köse S
    Mikrobiyol Bul; 2012 Oct; 46(4):553-9. PubMed ID: 23188569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical characteristics and treatment outcomes of vancomycin-resistant Enterococcus faecium bacteremia.
    Ye JJ; Shie SS; Cheng CW; Yang JH; Huang PY; Wu TS; Lee MH; Huang CT
    J Microbiol Immunol Infect; 2018 Dec; 51(6):705-716. PubMed ID: 29046248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of vancomycin, ciprofloxacin, daptomycin, and linezolid against coagulase-negative staphylococci bacteremia.
    Fajardo Olivares M; Hidalgo Orozco R; Rodríguez Garrido S; Rodríguez-Vidigal FF; Vera Tomé A; Robles Marcos M
    Rev Esp Quimioter; 2011 Jun; 24(2):74-8. PubMed ID: 21666998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraventricular daptomycin and intravenous linezolid for the treatment of external ventricular-drain-associated ventriculitis due to vancomycin-resistant Enterococcus faecium.
    Mueller SW; Kiser TH; Anderson TA; Neumann RT
    Ann Pharmacother; 2012 Dec; 46(12):e35. PubMed ID: 23232018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus.
    Pogue JM; Paterson DL; Pasculle AW; Potoski BA
    Infect Control Hosp Epidemiol; 2007 Dec; 28(12):1382-8. PubMed ID: 17994519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin.
    Cunha BA; Mickail N; Eisenstein L
    Heart Lung; 2007; 36(6):456-61. PubMed ID: 18005808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in clinical outcomes in patients with vancomycin-resistant enterococci according to linezolid susceptibility.
    Scheetz MH; Knechtel SA; Postelnick MJ; Malczynski M; Qi C
    Pharmacotherapy; 2010 Dec; 30(12):1221-8. PubMed ID: 21114389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations.
    Tsuji BT; Bulitta JB; Brown T; Forrest A; Kelchlin PA; Holden PN; Peloquin CA; Skerlos L; Hanna D
    J Antimicrob Chemother; 2012 Sep; 67(9):2182-90. PubMed ID: 22685161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates.
    Deville JG; Adler S; Azimi PH; Jantausch BA; Morfin MR; Beltran S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S158-63. PubMed ID: 14520141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Hall AD; Steed ME; Arias CA; Murray BE; Rybak MJ
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3174-80. PubMed ID: 22470111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vancomycin-resistant enterococcal bacteremia: comparison of clinical features and outcome between Enterococcus faecium and Enterococcus faecalis.
    Chou YY; Lin TY; Lin JC; Wang NC; Peng MY; Chang FY
    J Microbiol Immunol Infect; 2008 Apr; 41(2):124-9. PubMed ID: 18473099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis.
    Bounthavong M; Zargarzadeh A; Hsu DI; Vanness DJ
    Value Health; 2011; 14(5):631-9. PubMed ID: 21839399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Observational study of the epidemiology and outcomes of vancomycin-resistant Enterococcus bacteraemia treated with newer antimicrobial agents.
    McKinnell JA; Patel M; Shirley RM; Kunz DF; Moser SA; Baddley JW
    Epidemiol Infect; 2011 Sep; 139(9):1342-50. PubMed ID: 21073764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae.
    Luther MK; Arvanitis M; Mylonakis E; LaPlante KL
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4612-20. PubMed ID: 24867993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vancomycin-resistant Enterococcal Bloodstream Infections in Hematopoietic Stem Cell Transplant Recipients and Patients with Hematologic Malignancies: Impact of Daptomycin MICs of 3 to 4 mg/L.
    Chong PP; van Duin D; Bangdiwala A; Ivanova A; Miller WC; Weber DJ; Gilligan PH; Shea TC
    Clin Ther; 2016 Nov; 38(11):2468-2476. PubMed ID: 27771176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of linezolid, tigecycline, and daptomycin on methicillin-resistant Staphylococcus aureus blood isolates from adult patients, 2006-2008: stratified analysis by vancomycin MIC.
    Kao TM; Wang JT; Weng CM; Chen YC; Chang SC
    J Microbiol Immunol Infect; 2011 Oct; 44(5):346-51. PubMed ID: 21524980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.